Autologous Bone Marrow Stem Cells in Ischemic Stroke.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00535197
Recruitment Status : Completed
First Posted : September 26, 2007
Last Update Posted : February 17, 2016
Information provided by (Responsible Party):
Imperial College London

September 25, 2007
September 26, 2007
February 17, 2016
September 2007
July 2012   (Final data collection date for primary outcome measure)
Safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results [ Time Frame: Duration of study ]
safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results
Safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results [ Time Frame: Duration of study ]
Complete list of historical versions of study NCT00535197 on Archive Site
Improvement in clinical function as assessed by the Modified Rankin Score, and NIH stroke scale. [ Time Frame: Duration of study ]
Same as current
Not Provided
Not Provided
Autologous Bone Marrow Stem Cells in Ischemic Stroke.
A Phase I/II Safety and Tolerability Study Following the Autologous Infusion of Immuno-selected CD34+ Subset Bone Marrow Stem Cells Into Patients With Acute Total Anterior Circulation Ischaemic Stroke
The aim of the study is to determine the safety and tolerability of an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute total or partial anterior circulation syndrome (TACS/PACS).

The proposed trial will involve the recruitment of a total of 10 patients.

The cells will be collected from each subject recruited, via bone marrow sampling. CD34+ stem cells will then be isolated and harvested during a process of immuno-selection in accordance with the principles of Good Manufacturing Practice. The CD34+ cells will then be directly infused into the area of the stroke intra-arterially using the middle cerebral artery.

Initially, the investigator will monitor each patient for a period of 6 months post-stem cell infusion. Thereafter, they will revert to their previous treatment regime in the clinic.

Assessment of adverse events will be by physical examination and measurement of laboratory parameters. Assessment of efficacy will be by physical examination and the measurement of laboratory, CT and MRI parameters.

Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
  • Stroke, Acute
  • Infarction, Middle Cerebral Artery
Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery
intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2012
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptoms and signs of clinically definite acute stroke
  • Time of stroke onset is known and treatment can be started within 7 days of onset
  • CT or MRI brain scanning has reliably excluded both intracranial haemorrhage and structural brain lesions which can mimic stroke (e.g. cerebral tumour)
  • The stroke is severe and conforming to the TACS phenotype (weakness, homonymous hemianopia and a focal cognitive deficit (e.g. aphasia) or reduction in consciousness) or PACS phenotype (two out of the three TACS criteria)
  • An age range of 30-80 years old
  • Stroke confined to MCA territory on CT or MRI brain imaging
  • NIHSS score >/= 8

Exclusion Criteria:

  • Known defect of clotting or platelet function (but patients on anti-platelet agents can enrol)
  • Haematological causes of stroke
  • Severe co-morbidity
  • Hepatic or renal dysfunction
  • The patient is female and of childbearing potential (unless it is certain that pregnancy is not possible) or breast feeding
  • Hypo- or hyperglycaemia sufficient to account for the neurological symptoms; the patient should be excluded if their blood glucose is < 3.0 or > 20.0mmol/L
  • Patient is likely to be unavailable for follow-up e.g. no fixed home address
  • Patients with evidence of life threatening infection (e.g. HIV) or life threatening illness (e.g. advanced cancer)
  • Patient was already dependent in activities of daily living before the present acute stroke
  • Patients who have been included in any other clinical trial within the previous month
Sexes Eligible for Study: All
30 Years to 80 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
Imperial College London
Imperial College London
Not Provided
Principal Investigator: Nagy Habib, Professor Imperial College London U.K.
Imperial College London
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP